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Abstract
Insulin rapidly stimulates tyrosine kinase activity of its recep-
tor resulting in phosphorylation of its cytosolic substrate, insu-
lin receptor substrate-i (IRS-1), which in turn associates with
phosphatidylinositol 3-kinase (PI 3-kinase), thus activating
the enzyme. Glucocorticoid treatment is known to produce in-
sulin resistance, but the exact molecular mechanism is un-
known. In the present study we have examined the levels and
phosphorylation state of the insulin receptor and IRS-1, as well
as the association/activation between IRS-1 and PI 3-kinase in
the liver and muscle of rats treated with dexamethasone.
After dexamethasone treatment (1 mg/kg per d for 5 d),
there was no change in insulin receptor concentration in liver of
rats as determined by immunoblotting with antibody to the
COOH-terminus of the receptor. However, insulin stimulation
of receptor autophosphorylation determined by immunoblot-
ting with antiphosphotyrosine antibody was reduced by
46.7±9.1%. IRS-1 and PI 3-kinase protein levels increased in
liver of dexamethasone-treated animals by 73 and 25%, respec-
tively (P < 0.05). By contrast, IRS-1 phosphorylation was de-
creased by 31.3±10.9% (P < 0.05), and insulin stimulated PI
3-kinase activity in anti-IRS-1 immunoprecipitates was de-
creased by 79.5±11.2% (P < 0.02).
In muscle, the changes were less dramatic, and often in
opposite direction ofthose observed in liver. Thus, there was no
significant change in insulin receptor level or phosphorylation
after dexamethasone treatment. IRS-1 and PI 3-kinase levels
were decreased to 38.6 and 65.6%, respectively (P < 0.01 and P
< 0.05). IRS-1 phosphorylation showed no significant change
in muscle, but insulin-stimulated IRS-1 associated PI 3-kinase
was decreased by 41%. Thus, dexamethasone has differential
effects on the proteins involved in the early steps in insulin
action in liver and muscle. In both tissues, dexamethasone
treatment results in a reduction in insulin-stimulated IRS-1-as-
sociated PI 3-kinase, which may play a role in the pathogenesis
of insulin resistance at the cellular level in these animals. (J.
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Introduction
Insulin initiates its metabolic and growth-promoting effects by
binding to the a subunit of its tetrameric receptor, thereby
activating the tyrosine kinase in the ,B subunit ( 1, 2). This
catalyzes the intramolecular autophosphorylation of specific
tyrosine residues of the ,B subunit further enhancing the tyro-
sine kinase of the receptor toward other protein substrates (3).
In most cells, this primary event leads to the subsequent tyrosyl
phosphorylation ofa cytoplasmic protein with an apparent mo-
lecular mass between 160 and 185 kD called insulin receptor
substrate 1 (IRS-1 )' (3-5). Considerable evidence demon-
strates that insulin receptor tyrosine kinase activity and asso-
ciated IRS- 1 phosphorylation are essential for many, if not all,
of the biological effects of insulin ( 1, 6, 7). In cells in culture
and in vitro, phosphorylated IRS-1 associates with the lipid
metabolizing enzyme phosphatidylinositol 3-kinase (PI 3-ki-
nase) resulting in activation of the enzyme (8). Recently, our
laboratory has demonstrated that insulin is capable ofstimulat-
ing PI 3-kinase activity in liver and muscle ofthe intact animal
under physiological conditions and that IRS-l phosphoryla-
tion may play a significant role in the association/activation
with PI-3-kinase in vivo (9). Thus, the insulin receptor, IRS- 1
and PI-3-kinase represent three of the earliest steps in insulin
action, and each of these can be demonstrated in two of the
main target tissues for the metabolic actions of insulin in vivo,
liver and muscle.
It has long been known that glucocorticoid excess causes
insulin resistance (10-15). Hypercortisolemia is associated
with increased glucose production by the liver (10), decreased
peripheral glucose transport and utilization ( 1 1, 13), decreased
protein synthesis, and increased protein degradation in muscle
( 16). The mechanisms by which glucocorticoids exert these
effects are unknown. Changes in binding ofinsulin to its recep-
tor after glucocorticoid treatment have been observed, but do
not appear to account for the insulin resistance ( 12). Using
purified receptors and artificial substrates in vitro, decreased
insulin receptor phosphorylation and kinase activity have been
reported to occur in the liver but not in the muscle ofdexameth-
1. Abbreviations used in this paper: IRS- 1, insulin receptor substrate- 1;
PI 3-kinase, phosphatidylinositol 3-kinase; PI 3-P, PI 3-phosphate.
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asone-treated animals (17, 18). Using anti-IRS-I and anti-
phosphotyrosine antibodies, we recently showed that reduced
IRS- I phosphorylation may have an important role in another
state of insulin resistance, the ob/ob mouse model of type II
diabetes mellitus ( 19). The role ofthe expression or phosphor-
ylation of the endogenous substrate for the insulin receptor,
IRS-1, and its association/activation with PI 3-kinase in vivo
have not been examined in insulin resistance induced by gluco-
corticoids. In the present study, we have examined the phos-
phorylation state of the insulin receptor and IRS- 1 and the
activation of PI 3-kinase after insulin stimulation in vivo, as
well as the levels of these three proteins in liver and muscle of
dexamethasone-treated rats.
Methods
Materials
Reagents for SDS-PAGE and immunoblotting were from Bio-Rad Lab-
oratories (Richmond, CA). Hepes, antipain, aprotinin, leupeptin, pep-
statin, benzamidine hydrochloride, DTT, ATP, phosphatidylinositol-
4-monophosphate, Triton X-100, Tween 20, glycerol, and bovine
serum albumin (fraction V) were from Sigma Chemical Co. (St. Louis,
MO). Nonidet NP-40 was from Calbiochem (La Jolla, CA), phospha-
tidylinositol from Avanti (Alabaster, AL), silica gel thin-layer chroma-
tography plates from Merck (Gibbstown, NJ), protein A-sepharose
6MB from Pharmacia (Uppsala, Sweden), '251-protein A from ICN
Biomedicals (Costa Mesa, CA), y[32PIATP from NEN-Dupont (Wil-
mington, DE) and nitrocellullose paper (BA85, 0.2 gm) was from
Schleicher & Schuell (Keene, NH). Sodium amobarbital (Amytal)
and human recombinant insulin (Humulin R) were from Eli Lilly
(Indianapolis, IN). Polyclonal antiphosphotyrosine (apY) antibodies
were raised in rabbits and affinity purified on phosphotyramine col-
umns (20). Anti-IRS-I antibodies were raised in rabbits using a syn-
thetic peptide (Pep 80) derived from the amino acid sequence (YIP-
GATMGTSPALTGDEAA) corresponding to residues 489-507 ofthe
rat protein and affinity purified on a column prepared by coupling the
synthetic peptide to Affi-Gel 10 (Bio-Rad Laboratories) as previously
described (4). Anti-rat-PI 3-kinase antiserum was from UBI (Lake
Placid, NY). Antiinsulin receptor antibody was raised in rabbits using
a synthetic peptide derived from the amino acid sequence
(KKNGRILTLPRSNPS) corresponding to the C terminus of the rat
protein.
Methods
Animals and tissue extracts. Male rats ( 1 30-180 g) were allowed access
to standard rodent chow and water ad libitum. Rats were injected daily
at - 10:00 a.m. with 1 mg/kg dexamethasone or an equal volume of
saline (control group) for 5 d. Food was withdrawn 12-14 h before
experiments, and studies were performed in parallel for the control and
treated rats in each pair.
Rats were anesthetized with sodium amobarbital (15 mg/kg body
wt intraperitoneally) and used in experiments 10-15 min later, as soon
as anesthesia was assured by loss of pedal and corneal reflexes. The
abdominal cavity was opened, the portal vein exposed, and 1 ml of
normal saline (0.9% NaCi) with or without i0-5 M insulin was in-
jected. This is equivalent to injection of60 jig ofinsulin or - 1.5 U per
animal. At 30 s, the livers were removed, minced coarsely, and homoge-
nized immediately in l1OX vol of solubilization buffer A in a water
bath maintained at 100°C with a Polytron PTA 20S generator (model
PT 10/35; Brinkmann Instruments, Westbury, NY) operated at maxi-
mum speed for 30 s. The solubilization buffer A was composed of 1%
SDS, 50 mM Hepes (pH 7.4), 100 mM sodium pyrophosphate, 100
mM sodium fluoride, 10 mM EDTA, and 10 mM sodium vanadate.
The homogenate was heated further to boiling for 10 min and then
cooled in an ice bath for 40 min.
Approximately 90 s after injection, hindlimb muscles were excised
and frozen in liquid nitrogen. The frozen muscles were ground into a
fine powder and homogenized by a Polytron PTA 205 generator in 6x
vol of homogenization buffer B (same as buffer A, except that 1%
Triton-X 100 replaced 1% SDS, and 2 mM PMSF and 0.1 mg/ml
aprotinin were added) at 4VC. Both extracts were centrifuged at 55,000
rpm at 4VC in a rotor (model 70.1 Ti; Beckman Instruments, Inc,
Fullerton, CA) for 60 min to remove insoluble material, and the super-
natant was used as a sample.
In preliminary experiments, we showed that the maximal phos-
phorylation ofIRS- I occurs between 30 and 60 s in liver and between 1
and 4 min in muscle after intraportal insulin infusion. Using a 1-ml
vol, the concentrations of insulin that give maximal stimulation were
10-6 and I0-5 M insulin for liver and muscle, respectively. For these
experiments, we infused I0-5 M insulin and extracted liver at 30 s and
muscle at 1.5 min, thus sampling at the peak of phosphorylation
events. Dose-response studies of insulin receptor phosphorylation,
IRS- I phosphorylation, and IRS- I-associated PI 3-kinase activity after
intraportal infusion in the intact rat show that half-maximal stimula-
tion occurs at physiological postprandial concentration (9). In some
experiments, the livers were extracted in a identical way as muscle, and
the supernatant solutions of the muscle and livers were used for im-
munoprecipitation with anti-IRS-I antibody.
Protein analysis by immunoblotting. The samples were treated with
Laemmli sample buffer (21 ) with 100 mM DTT and heated in a boil-
ing water bath for 4 min. For total extracts, similar size aliquots of
sample ( 150 ,ug ofprotein) were subjected to SDS-PAGE (6% tris acryl-
amide) in a miniature slab gel apparatus (Bio-Rad Laboratories). Elec-
trotransfer of proteins from the gel to nitrocellulose was performed for
1 h at 90 V (constant) in the miniature transfer apparatus (Mini-Pro-
tean; Bio-Rad Laboratories) as described by Towbin et al. (22) but
with 0.02% SDS added to the transfer buffer to enhance elution ofhigh
molecular mass proteins. Nonspecific protein binding to the nitrocellu-
lose was reduced by preincubating the filter overnight at 4VC in block-
ing buffer (3% BSA, 10mM Tris (pH 7.5), 150 mM NaCl, and 0.02%
Tween 20). Prestained molecular weight standards were myosin (205
kD), 3-galactosidase (1 16 kD), bovine serum albumin (80 kD), and
ovalbumin (49.5 kD).
The nitrocellulose blot was incubated with antiphosphotyrosine an-
tibodies (apY, 0.3 jg/ml) or with anti-IRS-1 antibodies (0.3 jg/ml
ap8O) diluted in blocking buffer for 4 h at 22°C and washed for 60 min
with the blocking buffer without BSA. The blots were then incubated
with 2 jCi of '25I-protein A (30 jCi/jig) in 10 ml ofblocking buffer for
1 h at 22°C and washed again as described above for 2 h. I25I-protein A
bound to the antiphosphotyrosine and anti-IRS-I antibodies was de-
tected by autoradiography using preflashed Kodak XAR film with
Cronex Lightning Plus intensifying screens at -70°C for 12-48 h.
Band intensities were quantitated by optical densitometry (Molecular
Dynamics, Sunnyvale, CA) of the developed autoradiogram.
Phosphatidylinositol 3-kinase activity. PI 3-kinase activity was
measured by in vitro phosphorylation ofphosphatidylinositol as previ-
ously described (9, 23). After insulin injection into the portal vein, a
portion of the left lobe of liver and the hindlimb skeletal muscle were
removed and homogenized immediately in (1 /10 wt/vol) ice-cold sol-
ubilization buffer (buffer C) with a Polytron PTA 20S generator
(model PT 10/35; Brinkmann Instruments) operated at maximum
speed for 30 s and left to sit on ice for 30 min. The solubilization buffer
C was composed of 50 mM Hepes (pH 7.5), 137 mM NaCl, 1 mM
MgCl2, 1 mM CaCI2, 2 mM Na3VO4, 10 mM sodium pyrophosphate,
10 mM sodium fluoride, 2 mM EDTA, 1% NP-40, 10% glycerol, 2
jig/ml aprotinin, 10 ,jg/ml antipain, 5 ug/ml leupeptin, 0.5 jig/ml
pepstatin, 1.5 mg/ml benzamidine, and 34 ,jg/ml PMSF. Insoluble
material was removed by centrifugation at 15,000 rpm in a rotor
(model 7OTi; Beckman Instruments, Inc.) for 50 min. IRS-I was im-
munoprecipitated from aliquots of the supernatant containing 12 mg
protein with anti-IRS- I (0.3 jg/mil apep8O) or preimmune rabbit IgG
(0.3 jig/ml) followed by protein A-Sepharose 6MB. The immunopre-
cipitates were washed successively in PBS containing 1% NP-40 and
2066 M. J. A. Saad, F Folli, J. A. Kahn, and C. R. Kahn
Downloaded from http://www.jci.org on May 8, 2017.   https://doi.org/10.1172/JCI116803
100 AM Na3VO4 (three times), 100 mM Tris (pH 7.5) containing 500
mM LiC12, and 100 AM Na3VO4 (three times), and 10 mM Tris (pH
7.5) containing 100 mM NaCl, 1 mM EDTA, and 100 AM Na3VO4
(two times). The pellets were resuspended in 50 A1 of 10mM Tris (pH
7.5) containing 100 mM NaCl and 1 mM EDTA. 10 Al of 100 mM
MgC12 and 10 AI of phosphatidylinositol (2 Ag/IAl) sonicated in 10mM
Tris (pH 7.5) with 1 mM EGTA were added to each pellet.
The PI 3-kinase reaction was started by the addition of 10 4l of440
AM ATP containing 30 ACi [32p]ATP. After 10 min at room tempera-
ture with constant shaking, the reaction was stopped by the addition of
20 ,l 8 N HCl and 160 Al CHCl3/methanol ( 1:1). The samples were
centrifuged, and the lower organic phase was removed and applied to a
silica gel TLC plate (Merck) coated with 1% potassium oxalate. TLC
plates were developed in CHC13/CH3OH/H20/NH4OH (60:47:11.3:2),
dried, and visualized by autoradiography. The radioactivity in spots
that comigrated with a PI-4 standard was measured by Cerenkov
counting.
Other
Plasma glucose levels were determined with a glucose analyzer (Beck-
man Instruments) on blood samples from the cava vena obtained when
the animals were killed. Insulin was determined by a standard radioim-
munoassay. Protein determination was performed by the Bradford dye
method (24) using the Bio-Rad reagent and BSA as the standard.
Statistics
Experiments were always performed studying samples from the dexa-
methasone-treated animals in parallel with a control group. Compari-
sons were made using paired and unpaired t tests as appropriate. The
level of significance used was P < 0.05.
Results
Characteristics ofdexamethasone-treated rats. Table I summa-
rizes the body weight, plasma glucose, and serum insulin levels
of control and dexamethasone-treated rats. As previously ob-
served, glucocorticoid excess induces a state of insulin resis-
tance characterized by three- to fourfold increase in blood glu-
cose and a sixfold increase in plasma insulin levels. As a result,
the rats treated with dexamethasone also either lost or failed to
gain weight during the 5 d oftreatment period. Protein content
of the liver and muscle in steroid-treated rats were 251±9 and
239±39 mg/g tissue, respectively, and in controls, they were
276±17 and 217±28 mg/g tissue, respectively. The concentra-
tion of DNA per gram of hindlimb muscle was somewhat
higher in dexamethasone-treated rats compared to controls
(0.995 mg/g tissue vs 0.780 mg/g tissue, P < 0.05). There was
no difference in the DNA content of liver between dexametha-
sone-treated rats and controls (2.89 vs 3.17 mg/g tissue). All of
the quantitative data have been expressed normalized per mil-
ligrams ofprotein, however, in most situations, similar changes
were observed if the data were normalized by DNA content.
Table L Characteristics ofRats Studied
Body Plasma Serum
Groups n weight glucose insulin
g mg/dl UU/mI
Control 12 174±3 88±3 (6) 12±2 (6)
Dexamethasone 12 139±4 277±18 (6) 78±15 (6)
The data are represented as the mean±SEM.
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Figure 1. Insulin-stimulated tyrosine phosphorylation in intact mus-
cle from dexamethasone-treated rats. Rats were anesthetized and the
abdominal wall was incised to expose the viscera. I ml of normal sa-
line (lanes I and 3) or 10'w M insulin (lanes 2 and 4) was infused
into portal vein as a bolus injection, and 90 s later, muscles were ex-
cised and homogenized in extraction buffer B at 4VC as described in
Methods. After centrifugation, aliquots with same amount of protein
were resolved on 6% SDS-polyacrylamide gel, transferred to nitrocel-
lulose, and detected with antiphosphotyrosine antibody (A), anti-
IRS-1 antibody (B), or antiinsulin receptor antibody (C), and 1251_
protein A, and subjected to autoradiography. Dex, dexamethasone.
Effect of dexamethasone on insulin receptor and IRS-I
phosphorylation in muscle ofrats. Fig. 1 illustrates the protocol
for assessment of insulin receptor signaling in the intact rat.
Control and dexamethasone-treated rats were injected with sa-
line or insulin and after 30 and 90 s, the liver and hindlimb
skeletal muscle were removed and homogenized as described
in Methods, and the extracts subjected to SDS-PAGE under
reducing conditions and blotted to nitrocellulose membranes.
These blots could then be analyzed using antiinsulin receptor,
anti-IRS- 1, and antiphosphotyrosine antibodies, while parallel
extracts were assayed for PI 3-kinase activity and protein level.
Glucocorticoid-induced insulin resistance was associated
with a slight increase in insulin receptor levels in muscle, but
dramatically decreased IRS- 1 protein levels (Fig. 1 ). When the
results of eight similar experiments were subjected to scanning
densitometry, there was a 38.0±7.1% increase in insulin recep-
tor levels in muscle of dexamethasone-treated rats in samples
normalized per protein as determined by immunoblotting with
an antibody to the COOH terminus of the insulin receptor
(Fig. 2 A). By contrast, the levels of IRS- 1 protein in muscle
detected by immunoblotting were decreased by 61.4±5.0% in
rats treated with dexamethasone for 5 d (Fig. 2 A).
After in vivo insulin stimulation, the extent of insulin re-
ceptor autophosphorylation and IRS- I phosphorylation as de-
termined by immunoblotting with an antiphosphotyrosine an-
tibody were similar in muscle of the dexamethasone-treated
and control rats (Figs. 1 A and 2 B). However, when the data
were corrected for the change in number of insulin receptors
and IRS-1 molecules, the results are divergent, with a modest
decrease in the apparent stoichiometry of insulin receptor
phosphorylation but a more than twofold increase in the stoi-
chiometry of IRS-1 phosphorylation in the dexamethasone-
treated rats (Fig. 2 C). Thus, the increase in the phosphoryla-
tion ofIRS-1 protein as a result ofsteroid treatment might be of
limited biological significance since the number ofIRS-1 mole-
cules was dramatically decreased and the overall phosphoryla-
tion was slightly reduced when compared to controls (Fig. 1
A). In some experiments, there was a small difference in electro-
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Figure 2. Insulin receptor and IRS- I protein and tyrosine phosphor-
ylation levels (after in vivo insulin stimulation) in muscle of control
and dexamethasone-treated rats. Scanning densitometry of autora-
diograms was performed on eight experiments for insulin receptor
and IRS-I concentration and six experiments for tyrosine phosphor-
ylation levels ofboth. The data are expressed as mean±SEM. *Indi-
cates differences statistically significant at least at P < 0.05.
phoretic mobility in IRS- I band observed after insulin stimula-
tion because of the change in phosphorylation state, but this
was not consistently observed (Fig. 1 B).
Effect ofdexamethasone treatment on insulin receptor and
IRS-I phosphorylation in liver in rats. The effect ofdexametha-
sone treatment on insulin receptor and IRS- I in liver was dif-
ferent from that in muscle. There was no change in insulin
receptor level as detected by immunoblotting in liver of ani-
mals treated with dexamethasone, whether normalized per
protein or DNA (Figs. 3 C and 4 A). Furthermore, in contrast
to the decrease in IRS- I observed in muscle, immunoblotting
of liver extracts with antibodies to IRS-I revealed that the level
ofIRS-I was increased by 73.0±35.3% (P< 0.05) in dexameth-
asone-treated rats as compared to controls (Figs. 3 B and 4 A).
After dexamethasone treatment, changes were observed in
both basal and stimulated phosphorylation of the insulin re-
ceptor and IRS- I in liver. Before insulin stimulation, basal in-
sulin receptor phosphorylation was -36% higher in dexameth-
asone-treated rats than in controls, whereas after insulin stimu-
lation the extent of phosphorylation of insulin receptor was
reduced by 46.7±9.1% (P < 0.05) in treated rats compared to
controls (Figs. 3 A and 4 B). Accordingly, the tyrosine phos-
phorylation of IRS-1 was increased by 84±10% (P < 0.05)
before insulin stimulation in dexamethasone-treated rats while
the level of insulin-stimulated phosphorylation of IRS-I was
reduced by 31.3±10.9% (P < 0.05) in the presence ofglucocor-
ticoid excess (Figs. 3 A and 4 B). When the data are expressed
as a function ofthe amount ofinsulin receptor and IRS-I mole-
cules, there was a 40-50% in the stoichiometry ofinsulin recep-
tor and IRS-I phosphorylation in the liver of the dexametha-
sone-treated rats (Fig. 4 C).
Characteristics ofinsulin-stimulated PI 3-kinase activity of
liver and muscle in vivo in control and dexamethasone treated
rats. To determine the impact of changes in IRS- I expression
and phosphorylation on a further downstream effect, rats were
injected with saline or insulin as described above, extracts of
liver and hindlimb muscle were prepared and immunoprecipi-
tated with anti-IRS-I antibodies, and the washed immunopre-
cipitates were assayed in vitro for PI-3 kinase activity.
A low level of basal PI-3 kinase activity was present in the
anti-IRS-I immunoprecipitates from liver of control rats
correspondingto a relative specific activity of0.47±0.07 pmol/
mg protein per min. After insulin stimulation there was a rapid
and dramatic 25-fold increase in IRS-I associated PI-3 kinase
activity (Fig. 5 A). This is similar to magnitude to the increase
in IRS-I phosphorylation that occurs after insulin stimulation.
In liver ofdexamethasone-treated rats, there was a significantly
higher basal level ofIRS-I-associated PI-3 kinase activity com-
pared to control rats (specific activity = 1.47±0.15 vs
0.47±0.07 pmol/mg protein per min,P< 0.05) (Fig. 5). How-
ever, after insulin stimulation, there was only a 1.7-fold in-
crease in the PI 3-kinase activity in liver of dexamethasone-
treated rats. Thus, when compared with controls, the levels of
insulin-stimulated PI-3 kinase activity in anti-IRS- I immuno-
precipitates was reduced by 79.5% after dexamethasone treat-
ment (Fig. 5).
In muscle, IRS- I-associated PI 3-kinase activity in the ba-
sal state was slightly reduced in dexamethasone-treated rats
as compared to controls (specific activity = 1.60±0.37 vs
2.21±0.31 pmol/mg protein per min), although this difference
was not statistically significant. After insulin stimulation there
were a sevenfold stimulation in PI 3-kinase activity in control
rats, but only a fivefold stimulation in muscle of dexametha-
sone-treated rats despite the lower basal level. Thus, when
compared with controls, the absolute level of insulin-stimu-
lated PI 3-kinase activity in anti-IRS-I immunoprecipitates
was reduced by 41.2% in dexamethasone-treated rats (Fig. 5).
To determine if these changes might be caused by differ-
ences in the total amount ofPI 3-kinase in tissues ofdexametha-
sone-treated animals, we determined the level of total enzyme
protein by immunoblotting the tissue extracts with an antibody
to the 85-kD subunit ofPI 3-kinase. Based on immunoreactiv-
ity, the levels ofthis enzyme showed a tissue-specific regulation
similar to that observed with IRS- 1. PI 3-kinase protein levels
decreased to 65.5±14% of control values in muscle of dexa-
methasone-treated rats, but increased to 125.0±9.3% ofcontrol
in liver (Fig. 6). These changes paralleled the changes that
A Anfi-Phosph otrosine Antibody
Control Dcx
Insulin - + - +--
- 205
B Anti-IRS-il Antibody
Control Dex
Adaa_
_MP.
-116 C Anti-Insulin ReceptorAntibody
Control Dex
-80
1 2 3 4
Figure 3. Insulin-stimulated tyrosine phosphorylation in intact liver
from rats treated with dexamethasone. Rats were anesthetized and
the abdominal wall was incised to expose viscera. 1 ml of normal sa-
line (lanes and 3) or 1O0 M insulin (lanes 2 and 4) was injected
into portal vein as a bolus, and 30 s later, the liver was excised and
homogenized in extraction buffer A at 100°C for 5 min as described
in Methods. After centrifugation, aliquots with same amount of pro-
tein were resolved on 6% SDS-polyacrylamide gel, transferred to ni-
trocellulose, and detected with antiphosphotyrosine antibody (A),
anti-IRS-l antibody (B), or antiinsulin receptor antibody (C), and
'23I-protein A, and subjected to autoradiography.
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Figure 4. Insulin receptor and IRS-I protein and ty-
rosine phosphorylation levels (after in vivo insulin
stimulation) in liver of dexamethasone-treated rats.
Scanning densitometry was performed on autoradio-
grams from 8 experiments for insulin receptor con-
centration, 12 experiments for IRS- 1 concentration,
and 12 experiments for tyrosine phosphorylation of
both proteins. The data are expressed as mean±SEM.
*Indicates differences statistically significant at P
< 0.05.
occurred in IRS- 1 associated PI 3-kinase activity in the basal
state and suggest that the levels ofIRS- 1 and PI 3-kinase might
have an important role in the basal association/activation be-
tween IRS-1/PI 3-kinase.
Previous studies by our group (8, 9) have suggested that
there is a relatively stable high affinity interaction between IRS-
1 and the 85-kD subunit of the PI 3-kinase, such that both
proteins are coprecipitated by antibodies to either protein. In
samples from liver previously immunoprecipitated with anti-
IRS- antibody and immunoblotted with antiphosphotyrosine
A
PIP _-
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Insulin
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Control Dex Control Dex
r, -i I
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Figure 5. Insulin stimulation of IRS- I associated PI 3-kinase in liver
and muscle of control and dexamethasone-treated rats. The proteins
from liver and muscle were extracted and processed as described in
Methods, and incubated at 4°C with anti-IRS-l antibodies and pro-
tein A-Sepharose. PI 3-kinase in the washed immunoprecipitates was
assayed as described in Methods. The resulting labeled lipids were
extracted, separated by TLC, and visualized by autoradiography. [32P]-
phosphate incorporated into PI-3P was quantitated by Cerenkov
counting. (A) PI 3-kinase activity in anti-IRS- I immunoprecipitates
from liver and muscle after insulin stimulation. Ori indicates the ori-
gin; PIP, indicates the position ofmigration ofPI(4)P standard. (B)
Quantitation by Cerenkov counting of the [32P] phosphate incorpo-
rated into PI 3-P in immunoprecipitates from liver and muscle of
control and dexamethasone-treated rats. The results are expressed as
mean±SEM. The differences are statistically significant when control
and dexamethasone-treated rats before insulin stimulation in liver
and after insulin stimulation in liver and muscle are compared.
antibody, there was a >50% decrease in insulin stimulated IRS-
1 phosphorylation in dexamethasone-treated rats, confirming
the finding with whole tissue extracts (compare Figs. 3A and 7
A). When the same blot was subsequently incubated with anti-
bodies directed against the 85-kD subunit ofPI 3-kinase, there
was little detectable immunoreactivity in the basal state in nor-
mal animals, however this was increased in steroid-treated ani-
mals (Fig. 7 B), possibly because of the higher basal insulin
levels. After insulin stimulation, a band with the expected mo-
lecular weight ofregulatory subunit ofPI 3-kinase (85 kD) was
present in anti-IRS-l immunoprecipitates from liver of both
groups of rats consistent with a stable association of IRS- I and
PI 3-kinase. However, the amount of PI 3-kinase associated
with IRS-1 was reduced - 35% in dexamethasone-treated rats,
suggesting less association between IRS- 1 /PI 3-kinase. These
data are in accordance with the reduction in PI 3-kinase activ-
ity in immunoprecipitates of anti-IRS- 1 antibodies in liver of
these rats. The same experiment was also done for muscle, and
the results showed that after insulin stimulation the amount of
immunoreactive PI 3-kinase in immunoprecipitates of anti-
IRS- 1 antibodies was very similar in controls and in dexametha-
sone-treated rats (data not shown).
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Figure 6. PI 3-kinase levels in liver and muscle of control and dexa-
methasone-treated rats. The proteins from muscle and liver were ex-
tracted and processed as described in legends to Figs. 1 and 3, and
detected with anti-PI 3-kinase antibody (p85) and '251-protein A and
subjected to autoradiography. The bars represent mean±SEM of five
experiments for muscle and eight for liver. *Indicates differences from
control at P < 0.05.
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Figure 7. Immunoblotting of tyrosyl phosphorylated proteins and PI
3-kinase in anti-IRS- I immunoprecipitates from liver of control and
dexamethasone-treated rats. The protein from liver were extracted
and processed as described in legend of Fig. 3, solubilized and incu-
bated at 40C with anti-IRS antibody and Pansorbin. Immunoprecipi-
tated proteins were analyzed by immunoblotting with antiphospho-
tyrosine and anti-PI 3-kinase (85 kD subunit) antibodies and '25I-
protein A and subjected to autoradiography.
Discussion
The exact molecular events linking the insulin receptor tyro-
sine kinase to its final cellular actions remain poorly under-
stood. Over the past 2 yr, however, two newly recognized early
steps in the insulin action cascade have been defined at a molec-
ular level. First, insulin stimulates tyrosine phosphorylation of
a cytoplasmic protein of relative molecular mass between 165
and 185 kD, termed pp185 or IRS-1 (3-5). IRS-1 has been
shown to be a direct substrate of the insulin receptor both in
vivo and in vitro (25, 26). Furthermore, IRS-1 phosphoryla-
tion is decreased in intact cells expressing mutant insulin recep-
tors in direct proportion to the decrease in insulin receptor
kinase activity (27), and phosphorylation of IRS- I by the acti-
vated insulin receptor can be demonstrated by incubation of
baculovirus-produced IRS-I with purified insulin receptor
(25). IRS-1 has multiple potential serine, threonine, and tyro-
sine phosphorylation sites. Nine of the tyrosine phosphoryla-
tion sites have the repetitive sequence motifTyr-Met-Xxx-Met
(YMXM) or Tyr-Xxx-Xxx-Met (YXXM). When phosphory-
lated these sites, as well as others, appear to be involved in
noncovalent interactions of IRS-I with other signaling mole-
cules, particularly proteins containing SH2 domains (5, 8, 9, 28).
Thus, tyrosine phosphorylation of IRS- I leads to a second
early intracellular step in insulin action, an association ofIRS-
1 with the enzyme PI 3-kinase (8, 9). The association probably
occurs through phosphorylated YMXM motifs on IRS-1 and
the SH2 domain on the 85-kD subunit ofthe PI 3-kinase (8, 9).
Insulin also increases the cellular concentration of phosphati-
dylinositol 3-phosphate (PI 3-P), PI(3, 4)P2, and PI(3, 4,
5 )P3, indicating that the PI 3-kinase is activated during insulin
stimulation (29-31). The phosphorylation of IRS-1 and the
activation ofPI 3-kinase is decreased in cells expressing mutant
insulin receptors, and the decrease correlates with defective
insulin signaling, suggesting that these steps have an important
role in insulin action (23, 32). Recently, we demonstrated that
in a mouse model of insulin resistance and non-insulin-depen-
dent diabetes mellitus (the ob/ob mouse), insulin receptor,
IRS-I phosphorylation, and PI 3-kinase activity are reduced in
liver and muscle after insulin stimulation in vivo, pointing to a
postbinding defect in insulin action in these animals (19, 33).
The role of possible alterations in PI 3-kinase in insulin resis-
tant states has not yet been studied. In the present study, we
have evaluated the role of insulin receptor and IRS-1 phos-
phorylation and also the association/activation of PI 3-kinase
with IRS- I in liver and muscle of rats treated with dexametha-
sone.
Dexamethasone treatment of rats induces marked insulin
resistance as evidenced by altered glucose metabolism in both
peripheral tissues and liver, as well as decreased insulin-stimu-
lated amino acid uptake in muscle, and decreased lipogenesis
in adipocytes ( 10, 11, 15, 33a). This occurs with no significant
change in insulin receptor levels in liver and a small increase in
muscle. Dexamethasone has been shown to stimulate the syn-
thesis of insulin receptors in IM-9 lymphocytes (34) and in
cultured rat hepatocytes ( 35 ), and to decrease receptordegrada-
tion in 3T3 mouse fibroblasts (36). Thus, any downregulation
caused by increased circulating insulin levels in the dexametha-
sone-treated rats is probably offset by effects of glucocorticoids
on receptor synthesis and/or degradation.
Despite the normal number of receptors in liver and the
slight increase in receptors in muscle, we found - 40-50%
reduction in insulin receptor autophosphorylation after insulin
stimulation in vivo in both tissues. In muscle this may or may
not be of biological significance, since the decrease in receptor
phosphorylation was offset completely by the increase in recep-
tor number. These findings are consistent with previous studies
from our laboratory ( 17) and others ( 18, 37).
The changes in IRS-I levels in dexamethasone-treated rats
show a tissue-specific regulation decreasing by 61% in muscle
and increasing by 73% in liver. Recently, we demonstrated that
in hypoinsulinemic states of insulin resistance, such as fasting
and streptozotocin-induced diabetes, there is also a tissue-spe-
cific regulation of IRS-I ( 19), but the changes we observed
after dexamethasone administration are more marked than in
either of these conditions. The increase in levels of IRS-1 in
liver of dexamethasone-treated rats are in contrast to the de-
crease in the level of IRS- I in liver, which we have observed in
another hyperinsulinemic model of insulin resistance, the ob/
ob mouse ( 19). The differences in IRS- 1 levels between these
dexamethasone-treated rats and the ob/ob mouse suggest that
the level ofIRS-I in liver is modulated not only by the hyperin-
sulinemia, but also by high levels of dexamethasone, and that
the steroid effect dominates over the insulin effect. The domi-
nance of glucocorticoids over insulin is somewhat surprising,
since with other effects in liver, such as regulation of phos-
phoenolpyruvate-carboxy kinase, insulin dominates over dexa-
methasone (38, 39).
In addition to the differing effects of glucocorticoids on
IRS-I protein levels in liver and muscle, there is a differential
effect on the stoichiometry ofphosphorylation ofIRS- 1, which
is reduced by 60% in liver and increased by 136% in muscle of
dexamethasone-treated rats. The findings in liver are in agree-
ment with the decrease in insulin receptor phosphorylation in
kinase activity observed in that tissue, reinforcing our previous
observation that IRS-I phosphorylation may depend more on
insulin receptor phosphorylation and kinase activity than IRS-
1 protein levels ( 19). The finding in muscle is difficult to ex-
plain, but suggests that there can be differential coupling be-
tween insulin receptor autophosphorylation and its ability to
catalyze IRS-I phosphorylation. Since the concentration of
IRS-I in liver and muscle is normally similar to that of the
receptor, it is possible that the increase in the ratio of insulin
receptor protein to IRS-I protein in muscle ofdexamethasone-
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treated rats increases the efficiency of coupling between the
enzyme and its substrate.
Interestingly, PI 3-kinase levels also showed tissue specific
regulation in the dexamethasone-treated rats which was similar
but less dramatic than the glucocorticoid effect on IRS-1. The
increased levels of IRS-I and PI 3-kinase protein in liver and
the decreased levels in muscle in dexamethasone-treated rats
correlate with the changes in basal PI 3-kinase activity in anti-
IRS-I immunoprecipitates from these tissues and suggest that
the levels ofthese proteins has an important role in the process
ofassociation/activation in the basal state. The activation ofPI
3-kinase immunoprecipitated with anti-IRS-1 antibody after
insulin stimulation was dramatically reduced in both tissues of
dexamethasone-treated rats, but especially so in liver. This is in
accordance with the decrease in level ofphosphorylated IRS-
in muscle and the reduced stoichiometry of IRS-1 phosphory-
lation in liver.
The differences in insulin receptor and IRS- phosphoryla-
tion and also IRS-l associated PI 3-kinase activity between
liver and muscle in glucocorticoid-treated rats is interesting
and may reflect a tissue specific regulation of these three steps
in insulin action. Alternatively, this may reflect chronic expo-
sure of these tissues to different levels of insulin, since liver is
exposed to higher insulin levels than muscle. The reduction in
these initial steps after insulin binding in liver appears to be
regulatory, since similar alterations are observed in other ani-
mal models ofinsulin resistance associated with hyperinsuline-
mia ( 19) and in cultures of rat hepatoma cells chronically
treated with insulin (Saad et al., manuscript in preparation). It
is important to emphasize that in muscle, the major site of
glucose disposal (40), the decrease in PI 3-kinase activation in
dexamethasone-treated rats was less than that observed in liver,
suggesting that the insulin resistance in this tissue might also
involve steps distal to IRS-1 phosphorylation and IRS-l-asso-
ciated PI 3-kinase activity.
In summary, this study shows reduced expression and/or
phosphorylation of insulin receptor and IRS-1 may lead to re-
duced association and activation ofPI 3-kinase in vivo in liver
and muscle of dexamethasone-treated rats. These data suggest
that changes in these early steps in insulin signal transduction
may have an important role in the insulin resistance observed
in these animals.
Acknowledgments
The authors wish to thank Drs. Lewis Cantley (Tufts Medical School),
as well as Morris F. White and Montserrat Miralpeix (Joslin Diabetes
Center) for kindly providing antibodies to PI 3-kinase, anti-IRS-i1, and
antiphosphotyrosine, Jonathan Backer (Joslin Diabetes Center) for
many helpful suggestions, and Ms. Terri-Lyn Bellman for excellent
secretarial assistance.
This work was supported in part by National Institutes of Health
grants DK-33201 (C. R. Kahn), DK-36836 (Joslin's Diabetes and En-
docrinology Research Center grant), and the Marilyn Simpson Family
Trust. Dr. Franco Folli is a recipient of Dottorato di Ricerca, Univer-
sity of Milano, School of Medicine, Italy. During this work, Dr. Saad
held a fellowship from CNPq, Brazil.
References
1. Rosen, 0. 1987. After insulin binds. Science (Wash. DC). 237:1452-1458.
2. Kasuga, M., F. A. Karlsson, and C. R. Kahn. 1982. Insulin stimulates the
phosphorylation ofthe 95,000 dalton subunit ofits own receptor. Science (Wash.
DC). 215:185-187.
3. White, M. F., R. Maron, and C. R. Kahn. 1985. Insulin rapidly stimulates
tyrosine phosphorylation ofa M, 185,000 protein in intact cells. Nature (Lond.).
318:183-186.
4. Rothenberg, P. L., W. S. Lane, A. Karasik, J. Backer, M. F. White, and
C. R. Kahn. 1991. Purification and partial sequence analysis ofpp l85, the major
cellular substrate of the insulin receptor tyrosine kinase. J. Biol. Chem.
266:8302-8311.
5. Sun X. J., P. L. Rothenberg, C. R. Kahn, J. M. Backer, E. Araki, P. Wilden,
D. A. Cahill, B. J. Goldstein, and M. F. White. 1991. Structure of the insulin
receptor substrate IRS-1 defines a unique signal transduction protein. Nature
(Lond.). 352:73-77.
6. Maegawa, H., J. M. Olefsky, S. Thies, D. Boyd, A. Ullrich, and D. A.
McClain. 1988. Insulin receptors with defective tyrosine kinase inhibit normal
receptor function at the level of substrate phosphorylation. J. Biol. Chem.
263:12629-12637.
7. Ebina, Y., E. Araki, M. Taira, F. Shimada, M. Mori, C. S. Craik, K. Siddle,
S. B. Pierce, R. A. Roth, and W. J. Rutter. 1987. Replacement of lysine residue
1030 in the putative ATP-binding region ofthe insulin receptor abolishes insulin-
and antibody-stimulated glucose uptake and receptor kinase activity. Proc. Nat!.
Acad. Sci. USA. 84:704-708.
8. Backer, J. M., M. G. Myers, Jr., S. E. Shoelson, D. J. Chin, X. J. Sun, M.
Miralpeix, P. Hu, B. Margolis, E. Y. Skolnik, J. Schlessinger, and M. F. White.
1992. The phosphatidylinositol 3-kinase is activated by association with IRS-1
during insulin stimulation. EMBO (Eur. Mol. Biol. Organ.) J. 11:3469-3479.
9. Folli, F., M. J. A. Saad, J. M. Backer, and C. R. Kahn. 1992. Insulin
stimulation of phosphatidylinositol 3-kinase activity and association with IRS- I
in liver and muscle of the intact rat. J. Biol. Chem. 267:22171-22177.
10. Amatruda, J. M., J. N. Livingston, and D. H. Lockwood. 1985. Cellular
mechanisms in selected states ofinsulin resistance: human obesity glucocorticoid
excess and chronic renal failure. Diab. Metab. Rev. 3:293-317.
1 1. DePirro, R., A. Green, Y. Kao, and J. M. Olefsky. 1981. Effects ofpredni-
sone and dexamethasone in vivo and in vitro. Studies of insulin binding, deoxy-
glucose uptake and glucose oxidation in rat adipocytes. Diabetologia. 21:149-
153.
12. Kahn, C. R., I. D. Goldfine, D. M. Neville, Jr., and P. DeMeyts. 1978.
Alterations in insulin binding induced by changes in vivo in the levels of gluco-
corticoids and growth hormone. Endocrinology. 103:1054-1066.
13. Olefsky, J. M. 1975. Effect ofdexamethasone on insulin binding, glucose
transport, and glucose oxidation of isolated rat adipocytes. J. Clin. Invest.
56: 1499-1508.
14. Olefsky, J. M., J. Johnson, F. Lier, P. Jen, and G. M. Reaven. 1975. The
effects ofacute and chronic dexamethasone administration on insulin binding to
isolated rat hepatocytes and adipocytes. Metabolism. 24:517-527.
15. Caro, J. F., and J. M. Amatruda. 1982. Glucocorticoid-induced insulin
resistance. J. Clin. Invest. 69:866-875.
16. Rannels, S. R., and L. S. Jefferson. 1980. Effects of glucocorticoids on
muscle protein turnover in perfused rat hemicorpus. Am. J. Physiol. 238:E564-
E572.
17. Karasik, A., and C. R. Kahn. 1988. Dexamethasone-induced changes in
phosphorylation of the insulin and EGF receptors and their substrates in intact
rat hepatocytes. Endocrinology. 123:2214-2222.
18. Block, N. E., and M. G. Buse. 1989. Effects of hypercortisolemia and
diabetes on skeletal muscle insulin receptor function in vitro and in vivo. Am. J.
Physiol. 256:E39-E45.
19. Saad, M. J. A., E. Araki, M. Miralpeix, P. L. Rothenberg, M. F. White, and
C. R. Kahn. 1992. Regulation of insulin receptor substrate 1 in liver and muscle
of animal models of insulin resistance. J. Clin. Invest. 90:1839-1849.
20. Pang, D. T., B. R. Sharma, and J. A. Shafer. 1985. Purification of the
catalytically active phosphorylated form of insulin receptor kinase by affinity
chromatography with 0-phosphotyrosyl-binding antibodies. Arch. Biochem.
Biophys. 242:176-186.
21. Laemmli, U. K. 1970. Cleavage ofstructural proteins during the assembly
of the head of bacteriophage T4. Nature (Lond.). 227:680-685.
22. Towbin, H., J. Staehlin, and J. Gordon. 1979. Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proc. Natl. Acad. Sci. USA. 76:4350-4354.
23. Backer, J. M., G. G. Schroeder, C. R. Kahn, M. G. Myers, Jr., P. A.
Wilden, D. A. Cahill, and M. F. White. 1992. Insulin stimulation ofphosphatidyl-
inositol 3-kinase activity maps to insulin receptor regions required for endoge-
nous substrate phosphorylation. J. Biol. Chem. 267:1367-1374.
24. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of protein dye binding.
Anal. Biochem. 72:248-254.
25. Sun, X. J., M. Miralpeix, M. G. Myers, Jr., E. M. Glasheen, J. M. Backer,
C. R. Kahn, and M. F. White. 1992. Expression and function of IRS-I in insulin
signal transmission. J. Biol. Chem. 267:22662-22672.
26. Tobe, K., 0. Koshio, Y. Tashiro-Hashimoto, F. Takaku, Y. Akanuma,
and M. Kasuga. 1990. Immunological detection of phosphotyrosine-containing
proteins in rat livers after insulin injection. Diabetes. 39:528-533.
27. Wilden, P. A., J. M. Backer, C. R. Kahn, D. A. Cahill, G. J. Schroeder, and
Alterations ofInsulin Receptor Signaling in Steroid-treated Rats 2071
Downloaded from http://www.jci.org on May 8, 2017.   https://doi.org/10.1172/JCI116803
M. F. White. 1990. The insulin receptor with phenylalanine replacing tyrosine-
1 146 provides evidence for separate signals regulating cellulargrowth and metabo-
lism. Proc. Nadl. Acad. Sci. USA. 87:3358-3362.
28. Koch, C. A., D. Anderson, M. F. Moran, C. Ellis, and T. Pawson. 1991.
SH2 and SH3 domains: elements that control interactions ofcytoplasmic signal-
ing proteins. Science (Wash. DC). 252:668-674.
29. Ruderman, N. B., R. Kapeller, M. F. White, and L. C. Cantley. 1990.
Activation of phosphatidylinositol 3-kinase by insulin. Proc. Natl. Acad. Sci.
USA. 87:1411-1415.
30. Kelly, K. L., N. B. Ruderman, and K. S. Chen. 1991. Phosphatidylinositol
3-kinase in isolated rat adipocytes. Activation by insulin and subcellulardistribu-
tion. J. Biol. Chem. 267:3423-3428.
31. Endemann, G., K. Yonezawa, and R. A. Roth. 1990. Phosphatidylinositol
kinase or an associated protein is a substrate for the insulin receptor tyrosine
kinase. J. Biol. Chem. 265:396-400.
32. Kapeller, R., K. S. Chen, M. Yoakim, B. S. Schaffhausen, J. M. Backer,
M. F. White, L. C. Cantley, and N. B. Ruderman. 1991. Mutations in the juxta-
membrane region ofthe insulin receptor impair activation ofphosphatidylinosi-
tol 3-kinase by insulin. Mol. Endocrinol. 5:769-777.
33. Folli, F., M. J. A. Saad, J. M. Backer, and C. R. Kahn. 1993. Regulation of
phosphatidylinositol 3-kinase activity in liver and muscle of animal models of
insulin-resistant and muscle-deficient diabetes mellitus. J. Clin. Invest. 92:1787-
1794.
33a. Haber, R. S., and S. P. Weinstein. 1992. Role of glucose transporters in
glucocorticoid-induced insulin resistance. GLUT-4 isoform in rat skeletal muscle
is not decreased by dexamethasone. Diabetes. 41:728-735.
34. Fantus, G., G. A. Saviolakis, J. A. Hedo, and P. Gorden. 1982. Mecha-
nism of glucocorticoid-induced increase in insulin receptors of cultured human
lymphocytes. J. Biol. Chem. 257:8277-8283.
35. Salhanick, A. I., M. N. Knipp, and J. M. Amatruda. 1983. Dexametha-
sone stimulates insulin receptor synthesis in cultured rat hepatocytes. J. Biol.
Chem. 258:14130-14135.
36. Knutson, V. P. 1986. The acute and chronic effects ofglucocorticoids on
insulin receptor and insulin responsiveness. Transient fluctuations in intracellu-
lar receptor level parallel transient fluctuations in responsiveness. J. Biol. Chem.
261:10306-10312.
37. Truglia, J. A., G. R. Hayes, and D. H. Lockwood. 1988. Intact adipocyte
insulin-receptor phosphorylation and in vitro tyrosine kinase activity in animal
models of insulin resistance. Diabetes. 37:147-153.
38. O'Brien, R. M., and D. K. Granner. 1990. PEPCK gene as model of
inhibitory effects of insulin on gene expression. Diabetes Care. 13:327-339.
39. Gunn, J. M., S. M. Tilghman, R. W. Hanson, L. Reshef, and F. J. Ballard.
1975. Effects ofcyclic adenosine monophosphate dexamethasone and insulin on
phosphoenolpyruvate carboxykinase synthesis in reuber H-35 hepatoma cells.
Biochemistry. 14:2350-2357.
40. Ferrannini E., 0. Bjorkman, G. A. Reichard, Jr., A. Pilo, M. Olsson, J.
Wahren, and R. A. DeFronzo. 1985. The disposal of an oral glucose load in
healthy subjects. A quantitative study. Diabetes. 34:580-588.
2072 M. J. A. Saad, F. Folli, J. A. Kahn, and C. R. Kahn
Downloaded from http://www.jci.org on May 8, 2017.   https://doi.org/10.1172/JCI116803
